|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-8
|
|
pubmed:abstractText |
We performed a randomised controlled trial (RCT) to determine whether risedronate 35 mg once weekly prevents bone loss following an 8-week reducing course of prednisolone given for an exacerbation of inflammatory bowel disease (IBD). The greatest change in bone mineral density (BMD) was at Ward's triangle (WT), which fell by 2.2% in the placebo group, compared with a reduction of 0.8% in the risedronate group.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1433-2965
|
|
pubmed:author |
pubmed-author:BellAA,
pubmed-author:BrooklynT NTN,
pubmed-author:CreedT JTJ,
pubmed-author:FraserW DWD,
pubmed-author:KrienM JMJ,
pubmed-author:LinehanJJ,
pubmed-author:LockettMM,
pubmed-author:ProbertC S JCS,
pubmed-author:PrzemiosloRR,
pubmed-author:SmithsonJ EJE,
pubmed-author:TobiasJ HJH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
507-13
|
|
pubmed:meshHeading |
pubmed-meshheading:19484170-Absorptiometry, Photon,
pubmed-meshheading:19484170-Adult,
pubmed-meshheading:19484170-Bone Density,
pubmed-meshheading:19484170-Bone Density Conservation Agents,
pubmed-meshheading:19484170-Drug Administration Schedule,
pubmed-meshheading:19484170-Etidronic Acid,
pubmed-meshheading:19484170-Female,
pubmed-meshheading:19484170-Glucocorticoids,
pubmed-meshheading:19484170-Hip Joint,
pubmed-meshheading:19484170-Humans,
pubmed-meshheading:19484170-Inflammatory Bowel Diseases,
pubmed-meshheading:19484170-Lumbar Vertebrae,
pubmed-meshheading:19484170-Male,
pubmed-meshheading:19484170-Middle Aged,
pubmed-meshheading:19484170-Osteoporosis,
pubmed-meshheading:19484170-Prednisolone
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
|
|
pubmed:affiliation |
Department of Clinical Sciences at South Bristol, University of Bristol, Bristol, UK.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
